A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Oct 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 23 Apr 2017 Planned primary completion date changed from 1 Jul 2019 to 15 Jul 2019.